ZyVersa Therapeutics Selects Obesity And Related Metabolic Complications As Lead Indication For Inflammasome ASC Inhibitor IC 100

7/25/24 8:00:39 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ZVSA alert in real time by email

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, or "ZyVersa"))))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces that obesity and its related metabolic complications has been selected as the lead indication for Inflammasome ASC Inhibitor IC 100.

Get the next $ZVSA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ZVSA

Date	Price Target	Rating	Analyst

More analyst ratings

$ZVSA
Financials

Live finance-specific insights

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025.New Obesity, Metabolic & Inflammatory Disease Scientific Advisory Board (SAB) was formed in October 2024 to support development of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications.Two obesity proof-of-concept studies with IC 100 in diet-induced obesity (DIO) mouse models are planned, which will include assessment of various metabolic parameters. At least one of the studies is targeted to begin Q4-2024.IC 100 Investigational New Drug (IND) submission is planned for Q2-2025, and once cleared, will be followed by
11/14/24 8:10:00 AM ET
$ZVSA
Biotechnology: Pharmaceutical Preparations
Health Care
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024.Obesity with related metabolic complications selected as lead indication for Inflammasome ASC Inhibitor IC 100. Supportive data from preclinical study in atherosclerosis, a common obesity-related metabolic complication, is expected to be available H2-2024. IC 100 Investigational New Drug (IND) submission planned for Q4-2024, to be followed by initiation of a Phase 1 clinical trial in obesity with metabolic complications expected to begin Q1-2025.Raised approximately $0.8 million from exercise of investor warrants. WESTON, Fla., Aug. 09, 2024 (
8/9/24 4:40:00 PM ET
$ZVSA
Biotechnology: Pharmaceutical Preparations
Health Care
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
Key Highlights: Second research site selected to enhance enrollment in the Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease planned to begin H1-2024.GLP toxicology studies for Inflammasome ASC Inhibitor IC 100 scheduled to begin H1-2024, with planned Investigational New Drug (IND) submission Q4-2024, and Phase 1 clinical trial initiation Q1-2025.Atherosclerosis preclinical data readout for Inflammasome ASC Inhibitor IC 100 on schedule for H1-2024.Initiation of preclinical study to assess Inflammasome ASC Inhibitor IC 100 for obesity-associated metabolic comorbidities scheduled to begin Q2-2024 with completion expected by year's end.R
5/15/24 8:35:57 AM ET
$ZVSA
Biotechnology: Pharmaceutical Preparations
Health Care

$ZVSA
Press Releases

Fastest customizable press release news feed in the world

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
Strokes affect 795,000 people annually in the US. Obesity, a top risk factor for strokes, is associated with around one out of five strokes.Cardiac complications following a stroke are a leading cause of mortality and morbidity, second only to acute neurological injury.The pathomechanism underlying cardiac dysfunction following a stroke includes a surge of catecholamines, such as epinephrine, which induces inflammasome activation triggering a systemic inflammatory response.The published data showed that following a stroke, Inflammasome ASC Inhibitor IC 100 blocked AIM2 inflammasome activation and cell death (pyroptosis) in the heart and improved cardiac function.Data from this article suppor
11/20/24 7:55:00 AM ET
$ZVSA
Biotechnology: Pharmaceutical Preparations
Health Care
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025.New Obesity, Metabolic & Inflammatory Disease Scientific Advisory Board (SAB) was formed in October 2024 to support development of Inflammasome ASC Inhibitor IC 100 for obesity with metabolic complications.Two obesity proof-of-concept studies with IC 100 in diet-induced obesity (DIO) mouse models are planned, which will include assessment of various metabolic parameters. At least one of the studies is targeted to begin Q4-2024.IC 100 Investigational New Drug (IND) submission is planned for Q2-2025, and once cleared, will be followed by
11/14/24 8:10:00 AM ET
$ZVSA
Biotechnology: Pharmaceutical Preparations
Health Care
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes
During obesity, inflammasome-driven inflammation results in significant loss of pancreatic islet beta cell mass, severely impairing the insulin secreting capacity of the remaining beta cells.Preserving pancreatic islet beta cell function is key to prevention of insulin resistance and development of type 2 diabetes.The published data showed that inflammasome NLRP3 inhibition was protective of pancreatic islet beta cells, restoring their function and improving metabolic status in an obesity DIO mouse model.Data from this article support ZyVersa's development of Inflammasome ASC Inhibitor IC 100 for obesity and its associated comorbidities to be used as an add-on to incretin therapy. WESTON, F
11/5/24 7:00:00 AM ET
$ZVSA
Biotechnology: Pharmaceutical Preparations
Health Care

ZyVersa Therapeutics Selects Obesity And Related Metabolic Complications As Lead Indication For Inflammasome ASC Inhibitor IC 100

Chat with this insight

Recent Analyst Ratings for
$ZVSA

$ZVSA
Financials

Live finance-specific insights

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

$ZVSA
SEC Filings

$ZVSA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

ZyVersa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by ZyVersa Therapeutics Inc.

ZyVersa Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

SEC Form 4 filed by Director Freitag Gregory Gene

SEC Form 4 filed by Director Finizio Robert G

SEC Form 4 filed by Chief Executive Officer Glover Stephen C.

$ZVSA
Market Insights

Live Market Insights

ZyVersa Therapeutics Selects Obesity And Related Metabolic Complications As Lead Indication For Inflammasome ASC Inhibitor IC 100

ZyVersa Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 7.59%

ZyVersa Therapeutics Publish Paper In Angiogensis Peer-Review Journal That Demonstrated Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure And Function In Retinopathy Of Prematurity Animal Model

$ZVSA
Press Releases

Fastest customizable press release news feed in the world

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

$ZVSA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by ZyVersa Therapeutics Inc.

ZyVersa Therapeutics Selects Obesity And Related Metabolic Complications As Lead Indication For Inflammasome ASC Inhibitor IC 100

Chat with this insight

Recent Analyst Ratings for $ZVSA

$ZVSA Financials

Live finance-specific insights

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

$ZVSA SEC Filings

$ZVSA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

ZyVersa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by ZyVersa Therapeutics Inc.

ZyVersa Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

SEC Form 4 filed by Director Freitag Gregory Gene

SEC Form 4 filed by Director Finizio Robert G

SEC Form 4 filed by Chief Executive Officer Glover Stephen C.

$ZVSA Market Insights

Live Market Insights

ZyVersa Therapeutics Selects Obesity And Related Metabolic Complications As Lead Indication For Inflammasome ASC Inhibitor IC 100

ZyVersa Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 7.59%

ZyVersa Therapeutics Publish Paper In Angiogensis Peer-Review Journal That Demonstrated Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure And Function In Retinopathy Of Prematurity Animal Model

$ZVSA Press Releases

Fastest customizable press release news feed in the world

ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

$ZVSA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by ZyVersa Therapeutics Inc.

Recent Analyst Ratings for
$ZVSA

$ZVSA
Financials

$ZVSA
SEC Filings

$ZVSA
Insider Trading

$ZVSA
Market Insights

$ZVSA
Press Releases

$ZVSA
Large Ownership Changes